0.1% (placebo) Steady State: Achieved after 4-5 weeks of weekly dosing Safety: Nausea (68% at 4.5 mg), vomiting (32%), generally mild-moderate and transient Discontinuation: 14% discontinued due to GI adverse events Appetite Effects: Significant reductions in Visual Analogue Scale (VAS) hunger scores Publication: Lau DCW, et al
Therapeutically, simultaneously targeting both ferroptosis and autophagy pathways has emerged as a promising strategy to overcome treatment resistance in breast cancer
Magnesium helps convert carbohydrates, protein, and fats to energy, acts as a catalyst in thousands of enzymatic processes, regulates and maintains vascular tone, opposes calcium deposition into soft tissue, and is critical to proper bone formation. It regulates calcium and potassium metabolism, facilitates muscle constriction and relaxation, and assists in nerve transmission and conduction. For optimal absorption, this formulation uses magnesium combined with amino acid glycine to create a unique chelated compound that is highly bioavailable and well tolerated by even the most sensitive individuals
The BPC157 + TB500 + GHK-Cu Glow Blend is a combination peptide formulation composed of three well-characterized sequences commonly referenced in scientific and preclinical research
